Basosquamous carcinoma (BSC) is a rare form of skin cancer, which displays phenotypes of both basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). However, the molecular mechanisms behind this malignancy, as well as the genetic lineage, is highly debated. Potential clues to the origins of BSCs may be found by examining what drives the individual components of this form of cancer. BCCs are common locally invasive epithelial tumors characterized by inappropriate activation of the Hedgehog (HH) pathway and account for 60%-80% of skin cancers. In the absence of the Hedgehog ligand, the receptor Patched1 (PTCH1) inhibits Smoothened (SMO), which allows Suppressor of Fused (SUFU) to keep the GLI transcription factors within the cytoplasm. In the presence of HH-induced PTCH1 inhibition, SMO is able to suppress SUFU allowing the GLI transcription factors to enter the nucleus and regulate the transcription of downstream target genes associated with skin appendage development and homeostasis. Sporadic BCCs arise from progenitor cells found within the basal layer of the epidermis, predominantly from mutations in PTCH1 (73%) and SMO (20%) (Bonilla et al., 2016) . SMO inhibitors are used to treat advanced or metastatic BCCs. However, tumors can gain resistance to these drugs partly by undergoing squamatization (Ransohoff et al., 2015; Saintes et al., 2015; Zhao et al., 2015; Kuonen et al., 2019) .
SCC is the second most common form of skin cancer, comprising approximately 20% of cases, and typically arises from suprabasal keratinocytes. Unlike BCCs, SCCs tend to have a more complex genetic lineage because of the cellular heterogeneity of post-mitotic suprabasal cells at various stages of differentiation. Many genes are implicated in the progression of SCC, including TP53, NOTCH1/2, CDKN2A and members of the RAS/ MAPK pathway (Dotto and Rustgi 2016) . Monotherapies are not as effective in treating SCC, partly because of the large number of genetic alterations needed to promote proliferation, lose cellular connections and communication, reduce apoptosis, and stimulate a mutator phenotype to push keratinocytes to progress to SCC.
Although not as common as either BCC or SCC, BSCs comprise 1.2%-2.7% of skin cancer cases with a 5% incidence of metastasis (Garcia et al. 2009 ). These tumors have histological characteristics of both BCC and SCC but are routinely considered a type of BCC with a higher rate of reoccurrence and metastasis. Due to the low reported incidence rate of BSC, there is a lack of awareness of BSC pathology and molecular drivers of the disease. Chiang et al., 2019 provide a detailed genetic characterization of BSCs and find that HH pathway mutations are likely to initiate tumor formation with a surprising bifurcation event where ARID1A mutations may promote SCC driver mutations and squamatization that leads to the mixed nature of BSCs.
Genetic Lineage of BSC
Using targeted sequencing of 1641 cancer genes from 20 BSCs, whole exome sequencing from 16 BCCs, and a mixture of previously published whole exome and whole genome datasets from 52 SCCs, Chiang et al., 2019 found that BSC tumors more closely resembled BCCs than SCCs. Forty-five percent of BSC and 44% of BCC tumors contained deleterious mutations within PTCH1, whereas only 10% of SCCs showed PTCH1 mutations. Additionally, 15% of BSCs and 19% of BCCs carried mutations for MYCN, a downstream effector of HH signaling, while only 6% of SCCs showed MYCN mutations. Similar relationships were also seen with putative BCC drivers such as PTEN and PIK3CA. However, not all mutational drivers of BCC were found at comparable rates in BSC. For instance, the constitutively active SMO W535L mutation was only found in 5% of BSCs compared with 25% in BCCs. Other putative BCC drivers, such as PPP6C, GRIN2A, and PREX2, showed similar mutational frequencies between BSC and SCC.
When comparing the mutational frequencies of SCC driver genes, BSCs were more similar to BCC than SCC. For instance, major SCC driver genes, such as CDKN2A, KRAS, NRAS, and HRAS, were not mutated in either BSC or BCC. The NOTCH genes were also mutated less frequently in BSC (w18%) than SCC, where approximately 42% of SCC and 28% of BCC tumors showed NOTCH1 and NOTCH2 mutations. However, some oncogenic drivers showed more similarity between BSC and SCC (e.g., TP53, TP63, and RAC1).
Interestingly, 45% of BSCs displayed mutations in ARID1A, a component of the SWI/SNF chromatin remodeling complex. This was a significantly greater amount than the 19% of BCCs and SCCs that harbored ARID1A mutations. ARID1A disruption promotes mammalian cell proliferation and regeneration, imparting a plasticity that enhances cell survival in part by reducing the restrictive nature of chromatin remodeling in terminally differentiated cells (Sun et al. 2016 ). ARID1A mutations may allow keratinocytes to sample different fates and undergo squamatization under selective pressure, an event seen in the clinic where SMO inhibitor treatment can promote de novo SCC development from BCC tumors (Ransohoff et al., 2015; Saintes et al., 2015; Zhao et al., 2015) .
ERK1/2 activation in BSC
Pathway switching from HH to RAS/ MAPK is one route that HH-dependent tumors can take to evade SMO inhibition (Zhao et al., 2015) . In medulloblastoma, pathway switching circumvents HH pathway dependency and enhances metastatic behavior, whereas pathway switching in BCC can lead to squamatization. Furthermore, loss of primary cilia, a microtubule-based signaling organelle that is essential for highly sustained HH signaling, can promote RAS/MAPK pathway activation to push the BCCto-SCC transition (Kuonen et al., 2019) . Here, primary cilia may serve as a biomarker for SMO inhibitor efficacy where BCCs with primary cilia display high GLI1 signal and are responsive to SMO inhibition, whereas BCCs without primary cilia can display high RAS/MAPK signal, are non-responsive to SMO inhibition, and may squamatize. Together, this data suggests a balance between HH and RAS/MAPK signaling that dictates tumor fates ( Figure 1) . The authors showed a similar relationship between the two pathways, where basaloid cells within BSC tumors displayed high levels of nuclear GLI1 and low levels of p-MEK, and squamatized areas showed greater levels of p-MEK and the loss of nuclear GLI1. Basaloid cells adjacent to the squamatized areas had an intermediate state with higher levels of p-ERK staining, while maintaining GLI1 levels, suggesting that RAS/MAPK pathway activation through p-ERK and p-MEK may serve as biomarkers for the efficacy of SMO inhibitors in HHdependent tumors.
Therapeutic targets for BSCs
The balance between the HH and RAS/ MAPK pathways illustrates a potential problem when treating BCCs, where SMO inhibitors may push HHdependent cancers to adopt additional pathways to maintain tumor growth. The absence of RAS/MAPK pathway activation or ARID1A mutations in BCC-like tumors may serve as a "go" signal to use SMO inhibitors with a low probability of drug resistance, whereas the presence of either biomarker should instill caution toward the efficacy of SMO inhibitors. For those tumors with ARID1A mutations, the recent success of PARP inhibitors on ARID1A-deficient cancer cells may serve as an alternative therapeutic strategy to treat BSCs (Shen et al. 2015) . In fact, targeting DNA repair mechanisms may be therapeutically useful to treat genomically unstable BCCs, broadening their impact to a b Figure 1 . Genetic lineage of BSC. (a) Activating HH pathway mutations initially drive formation of BCCs. Acquisition of de novo ARID1A mutations or other chromatin remodeling mutations under pharmacological SMO inhibition drive cellular plasticity, pushing basal cells to undergo squamatization and leading to BSC formation.(b) Within the BCC zone, high levels of HH signaling, low RAS/MAPK pathway activity, and high levels of ciliation drive tumor growth. Within the SCC zone, RAS/MAPK signaling increases with a concomitant reduction in HH pathway activity and ciliation. Within the Transition zone, cells begin to show higher levels of RAS/MAPK pathway activity while maintaining HH signaling. The levels of ciliation are unknown.
Clinical Implications
ARID1A mutations and RAS/MAPK activation may serve as biomarkers for BSC and likely promote resistance to SMO inhibitors. PARP inhibition may be a viable therapeutic for BSC and unstable sporadic BCC. COMMENTARY www.jidonline.org 2259 include the majority of skin cancers (Nguyen and Atwood, 2018) .
